The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group.

The prognostic importance of tumor size was studied in 510 patients with malignant glioma (80% with glioblastoma multiforme) in the Valid Study Group of Study 80-01 of the Brain Tumor Study Group (now the Brain Tumor Cooperative Group [BTCG]). The endpoint was length of survival from randomization, which occurred within 3 weeks of definitive surgery. Following randomization, patients were scheduled to receive radiotherapy (RT) (6,020 cGy) during a 7-week period, along with continuing courses of chemotherapy. Computed tomographic (CT) scan information was available for 124 patients preoperatively, 300 patients postoperatively (preradiation), and 218 patients 9 weeks post-RT (+/- 3 weeks). Tumor size was determined as area (length x width) on the contrast-enhanced scan and survival was compared by log rank statistics. Preoperative tumor area was unrelated to survival (P = .48), but postoperative area was significantly prognostic (P less than .0001); the smaller the residual tumor, the longer the patient lived. Patients with a 75% or greater resection, as determined by measuring the difference between the preoperative and the postoperative scans, tended to have better survival, but the difference was not significant (P = .16). The post-RT area was strongly related to survival (P less than .00001). The percent change in area between the pre- and post-RT scans was also prognostic. Tumor size was of prognostic importance independent of the other known prognostic variables: age, Karnofsky performance score, and whether the tumor was glioblastoma or anaplastic astrocytoma. We conclude that the amount of tumor remaining after surgery is an important baseline variable at the start of RT, and that the tumor size 9 weeks following RT is also prognostic. Surgical resection is most important when it leaves the least amount of residual tumor.

[1]  W F Taylor,et al.  Radiotherapy of intracranial astrocytomas: analysis of 417 cases treated from 1960 through 1969. , 1979, Neurosurgery.

[2]  J. Martin,et al.  A study of 211 patients with verified glioblastoma multiforme. , 1948, Transactions of the American Neurological Association.

[3]  J. Marks,et al.  Prognostic significance of lesion size for glioblastoma multiforme. , 1979, Radiology.

[4]  M. Rathbone,et al.  Postoperative contrast enhancement in patients with brain tumor , 1985, Annals of neurology.

[5]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[6]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[7]  P. Bucy,et al.  The treatment of glioblastoma multiforme of the brain. , 1967, Journal of neurosurgery.

[8]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[9]  D. Cox Regression Models and Life-Tables , 1972 .

[10]  M. D. de Leon,et al.  CT prognostic criteria of survival after malignant glioma surgery. , 1983, AJNR. American journal of neuroradiology.

[11]  D. Norman,et al.  Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. , 1980, Journal of neurosurgery.

[12]  H. Cushing Intracranial tumours : notes upon a series of two thousand verified cases with surgical-mortality percentages pertaining thereto , 1932 .

[13]  M. Salcman Resection and reoperation in neuro-oncology. Rationale and approach. , 1985, Neurologic clinics.

[14]  M. Netsky,et al.  The longevity of patients with glioblastoma multiforme. , 1950, Journal of neurosurgery.

[15]  F. Ederer,et al.  Maximum utilization of the life table method in analyzing survival. , 1958, Journal of chronic diseases.